Clinical Trials Browser

Terminated × Lung Diseases × Nivolumab × Clear all

NCT03406715 2023-03-30

Combination Immunotherapy-Ipilimumab-Nivolumab-Dendritic Cell p53 Vac - Patients With Small Cell Lung Cancer (SCLC)

Phase 2 Terminated

14 enrolled 12 charts

Lung Diseases, Lung Neoplasms, Small Cell Lung Carcinoma